Pipeline

Medigene’s proprietary End-to-End Platform enables the development of best-in class differentiated T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications that are optimized for safety, efficacy and durability. Medigene develops these therapies on its own or in partnership.

Medigene´s Own Programs
Program
Target
Product Armoring & Enhancement
  • Discovery
  • Lead Candidate
  • CTA/IND-enabling
  • Clinical Studies
Next Milestone

MDG1015

NY-ESO-1 / LAGE-1a

PD1-41BB

HLA-A*02

CTA / IND 2H 2024

Medigene’s lead candidate targeting NY-ESO-1 combined with our PD1-41BB costimulatory switch protein. 

MDG2011

KRAS-G12V

PD1-41BB

HLA-A*11

IND enabling

MDG2021

KRAS-G12D

PD1-41BB or CD40L-CD28

HLA-A*11

Lead selection 1H 2024

MDG2012

KRAS-G12V

PD1-41BB or CD40L-CD28

HLA-A*03

Lead selection 2025

MDG20XX

KRAS*

PD1-41BB or CD40L-CD28

HLA*

Undisclosed

Medigene exploring additional multiple HLAs.

MDG10XX

undisclosed

undisclosed

HLA*

Undisclosed

Generation of TCR-T cells targeting appropriate antigens with several different HLA types each developed and improved with our armoring and enhancement technologies.

Medigene´s Partnered Programs

Program
Target
Product Armoring & Enhancement
  • Discovery
  • Lead Candidate
  • CTA/IND-enabling
  • Clinical Studies
Next Milestone

MAGE-A4

Yes**

HLA-A*02

FIH***study recruiting

Exclusively partnered with 2seventy bio.

PRAME

Yes

HLA-A*02

Undisclosed

Exclusively partnered with BioNTech.  Also includes non-exclusive licenses to our optimization technologies

NY-ESO-1

Yes

HLA-A2

Set by Hongsheng Sciences

Exclusively partnered with Hongsheng Sciences.

Program
Target
Optimizations​
  • Discovery
  • Lead Candidate
  • CTA/IND-enabling
  • Clinical Studies
Next Milestone

MDG1011

PRAME

No

HLA-A2

Partnering

NY-ESO-1

No

HLA-A2

Set by Hongsheng Sciences

Exclusively partnered with Hongsheng Sciences.

*MDG20XX – Medigene exploring multiple, additional HLAs and /or G12 mutations;
**Enhancement not licensed from Medigene
***http://3. Clinicaltrials.gov NCT06170294

KEY CATALYSTS ANTICIPATED THROUGH END OF 2026*

* Milestones >Q4 2024 are subject to financing

INTELLECTUAL PROPERTY

Medigene’s proprietary End-to-End Platform for identifying, selecting and engineering best-in-class TCRs is protected by exclusively in-licensed and proprietary patents in Europe, North America and Japan. Patent rights individually protect all TCRs generated by our proprietary TCR platform technology in countries selected based on our corporate commercial long-term strategy. In addition, Medigene is constantly developing improved methods and technologies across our End-to-End Platform to produce the best TCR therapies. These methods are also subject to new patent protection in line with our company’s patent strategy.